Logo image of MBRX

MOLECULIN BIOTECH INC (MBRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MBRX - US60855D3098 - Common Stock

0.4272 USD
+0.01 (+1.35%)
Last: 11/21/2025, 8:00:01 PM
0.425 USD
0 (-0.51%)
After Hours: 11/21/2025, 8:00:01 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MBRX. MBRX was compared to 535 industry peers in the Biotechnology industry. MBRX may be in some trouble as it scores bad on both profitability and health. MBRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MBRX had negative earnings in the past year.
In the past year MBRX has reported a negative cash flow from operations.
In the past 5 years MBRX always reported negative net income.
In the past 5 years MBRX always reported negative operating cash flow.
MBRX Yearly Net Income VS EBIT VS OCF VS FCFMBRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -122.96%, MBRX is doing worse than 80.00% of the companies in the same industry.
Industry RankSector Rank
ROA -122.96%
ROE N/A
ROIC N/A
ROA(3y)-85.68%
ROA(5y)-67.14%
ROE(3y)-177.93%
ROE(5y)-130.32%
ROIC(3y)N/A
ROIC(5y)N/A
MBRX Yearly ROA, ROE, ROICMBRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MBRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBRX Yearly Profit, Operating, Gross MarginsMBRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for MBRX has been increased compared to 1 year ago.
MBRX has more shares outstanding than it did 5 years ago.
MBRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MBRX Yearly Shares OutstandingMBRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
MBRX Yearly Total Debt VS Total AssetsMBRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

MBRX has an Altman-Z score of -14.23. This is a bad value and indicates that MBRX is not financially healthy and even has some risk of bankruptcy.
MBRX has a Altman-Z score of -14.23. This is in the lower half of the industry: MBRX underperforms 78.13% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.23
ROIC/WACCN/A
WACCN/A
MBRX Yearly LT Debt VS Equity VS FCFMBRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.15 indicates that MBRX should not have too much problems paying its short term obligations.
The Current ratio of MBRX (1.15) is worse than 86.36% of its industry peers.
A Quick Ratio of 1.15 indicates that MBRX should not have too much problems paying its short term obligations.
MBRX has a Quick ratio of 1.15. This is amonst the worse of the industry: MBRX underperforms 85.98% of its industry peers.
Industry RankSector Rank
Current Ratio 1.15
Quick Ratio 1.15
MBRX Yearly Current Assets VS Current LiabilitesMBRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 80.73% over the past year.
EPS 1Y (TTM)80.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MBRX will show a very strong growth in Earnings Per Share. The EPS will grow by 20.87% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y87.51%
EPS Next 2Y37.82%
EPS Next 3Y24.43%
EPS Next 5Y20.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MBRX Yearly Revenue VS EstimatesMBRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2029 2030 2031 2032 50M 100M 150M 200M
MBRX Yearly EPS VS EstimatesMBRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MBRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MBRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MBRX Price Earnings VS Forward Price EarningsMBRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBRX Per share dataMBRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2

4.3 Compensation for Growth

MBRX's earnings are expected to grow with 24.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.82%
EPS Next 3Y24.43%

More info and screens

0

5. Dividend

5.1 Amount

MBRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOLECULIN BIOTECH INC

NASDAQ:MBRX (11/21/2025, 8:00:01 PM)

After market: 0.425 0 (-0.51%)

0.4272

+0.01 (+1.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-19 2026-03-19/amc
Inst Owners1.18%
Inst Owner Change79.87%
Ins Owners2.84%
Ins Owner Change25.99%
Market Cap21.75M
Revenue(TTM)N/A
Net Income(TTM)-26.55M
Analysts82.22
Price Target6.8 (1491.76%)
Short Float %17.99%
Short Ratio2.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.05%
Min EPS beat(2)-32.22%
Max EPS beat(2)-21.89%
EPS beat(4)1
Avg EPS beat(4)0.72%
Min EPS beat(4)-32.22%
Max EPS beat(4)71.5%
EPS beat(8)4
Avg EPS beat(8)5.04%
EPS beat(12)6
Avg EPS beat(12)6.29%
EPS beat(16)9
Avg EPS beat(16)9.7%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)29.52%
EPS NY rev (1m)0%
EPS NY rev (3m)46.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.23
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0
BVpS-0.14
TBVpS-0.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -122.96%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-85.68%
ROA(5y)-67.14%
ROE(3y)-177.93%
ROE(5y)-130.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.15
Quick Ratio 1.15
Altman-Z -14.23
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)53.16%
Cap/Depr(5y)71.82%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.14%
EPS Next Y87.51%
EPS Next 2Y37.82%
EPS Next 3Y24.43%
EPS Next 5Y20.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.55%
EBIT Next 3Y-6.25%
EBIT Next 5Y27.59%
FCF growth 1Y17.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.84%
OCF growth 3YN/A
OCF growth 5YN/A

MOLECULIN BIOTECH INC / MBRX FAQ

What is the fundamental rating for MBRX stock?

ChartMill assigns a fundamental rating of 1 / 10 to MBRX.


What is the valuation status of MOLECULIN BIOTECH INC (MBRX) stock?

ChartMill assigns a valuation rating of 1 / 10 to MOLECULIN BIOTECH INC (MBRX). This can be considered as Overvalued.


What is the profitability of MBRX stock?

MOLECULIN BIOTECH INC (MBRX) has a profitability rating of 0 / 10.


What is the earnings growth outlook for MOLECULIN BIOTECH INC?

The Earnings per Share (EPS) of MOLECULIN BIOTECH INC (MBRX) is expected to grow by 87.51% in the next year.